PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

ABSTRACT:

Purpose

Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T cells to inhibit T-cell immunity. Immunotherapies targeting the PD-1/PD-L1 pathway have shown durable antitumor effects in a subset of patients with solid tumors. PD-L1 can be expressed by Reed-Sternberg cells comprising classical Hodgkin lymphoma (CHL) and by malignant B cells comprising EBV-positive posttransplant lymphoproliferative disorders (PTLD). We sought to determine whether the expression of PD-L1 represents a general strategy of immune evasion among aggressive B-cell lymphomas and virus- and immunodeficiency-associated tumors.

Experimental design

Using novel antibodies and formalin-fixed, paraffin-embedd

SUBMITTER: Chen BJ 

PROVIDER: S-EPMC4102335 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature